Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDXK | O00764 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16213170 | 0.83 | — | — | |
| SCHEMBL16196135 | 0.80 | — | — | |
| SCHEMBL27451735 | 0.78 | — | — | |
| SCHEMBL4487443 | 0.77 | PDXK (0.36) | PDXK | |
| SCHEMBL17802124 | 0.77 | — | — | |
| SCHEMBL17748267 | 0.76 | CD274 (0.38) | — | |
| SCHEMBL14576611 | 0.76 | PDXK (0.39) | PDXK | |
| SCHEMBL1938836 | 0.75 | — | — | |
| SCHEMBL5794503 | 0.74 | PDXK (0.37) | PDXK | |
| SCHEMBL31491027 | 0.74 | PDXK (0.34) | PDXK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615847-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | Merck Sharp & Dohme LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2024103010-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | MERCK SHARP & DOHME LLC (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20240025915-A1 | SOLID FORMS OF 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL)-3,5-DIHYDRO-2H-PYRIDO[3,4-F][1,4]OXAZEPINE-9-CARBONITRILE | DENALI THERAPEUTICS INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025915-A1 | SOLID FORMS OF 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL)-3,5-DIHYDRO-2H-PYRIDO[3,4-F][1,4]OXAZEPINE-9-CARBONITRILE | DENALI THERAPEUTICS INC. (US) | 2024-01-25 | — | — | US | disclosed |
| EP-2991985-B1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-06-13 | — | — | EP | disclosed |
| EP-2991985-B1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-06-13 | — | — | EP | disclosed |
| EP-2991985-A1 | ALDOSTERONE SYNTHASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2016-03-09 | — | — | EP | disclosed |
| US-9181272-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| US-9181272-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| US-9181272-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| WO-2014179186-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179186-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-06 | — | — | WO | disclosed |
| US-20140323468-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323468-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323468-A1 | ALDOSTERONE SYNTHASE INHIBITORS | CYP11B1, CYP21A2, REN | PDXK 693/4885 |
| US-20240025915-A1 | SOLID FORMS OF 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL)-3,5-DIHYDRO-2H-PYRIDO[3,4-F][1,4]OXAZEPINE-9-CARBONITRILE | CACNA1B, CACNA1C, CACNB3 | PDXK 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.